XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Reporting
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s structure is aligned with how the chief operating decision maker (“CODM”) reviews the business, makes investing and resource allocation decisions and assesses operating performance. The Company’s two reportable segments are: (i) GeneDx inclusive of Legacy GeneDx and Legacy Sema4 data revenues and associated costs and (ii) Legacy Sema4 diagnostics. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. The Legacy Sema4 diagnostics segment provided reproductive and women’s health and somatic oncology diagnostic testing and screening products and has been completely shut down.
The CODM evaluates segment performance based on revenue and adjusted gross profit.
Three months ended September 30,
20242023
GeneDxLegacy Sema4TotalGeneDxLegacy Sema4Total
Revenue$76,622 $252 $76,874 $50,350 $2,953 $53,303 
Adjusted cost of services27,370 — 27,370 26,079 225 26,304 
Adjusted gross profit (1)
49,252 252 49,504 24,271 2,728 26,999 
Reconciliations:
Depreciation and amortization1,495 — 1,495 1,613 — 1,613 
Stock-based compensation174 — 174 75 — 75 
Restructuring charges6 — 6 52 — 52 
Gross profit$47,577 $252 $47,829 $22,531 $2,728 $25,259 
Nine months ended September 30,
20242023
GeneDxLegacy Sema4TotalGeneDxLegacy Sema4Total
Revenue$207,007 $2,803 $209,810 $136,269 $8,879 $145,148 
Adjusted cost of services77,992 145 78,137 81,357 2,305 83,662 
Adjusted gross profit (1)
129,015 2,658 131,673 54,912 6,574 61,486 
Reconciliations:
Depreciation and amortization3,119 — 3,119 3,322 113 3,435 
Stock-based compensation308 — 308 631 (1,971)(1,340)
Restructuring charges54 — 54 108 31 139 
Gross profit$125,534 $2,658 $128,192 $50,851 $8,401 $59,252 
(1)Adjusted cost of services and adjusted gross profit exclude depreciation and amortization expense, stock-based compensation expense and restructuring costs.
Management manages assets on a total company basis, not by reporting segment. The CODM does not regularly review any asset information by reporting segment and, accordingly, the Company does not report asset information by reporting segment.